Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT02961504

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
  • Healios K.K. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02961504
Other papers using this trial's data
  • Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial JAMA neurology, 2024-02-01 DOI, PubMed 38227308, PMC10792497 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02961504. Randomized; quadruple masking; primary purpose treatment. Start 2017-11-15 (actual); primary completion 2021-03-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
Acronym
TREASURE
Condition
Stroke, Acute
Intervention (Biological)
HLCM051
Intervention (Biological)
Placebo
Lead sponsor
Healios K.K. (class: industry)

Record details

Record id
cardio:ct-nct02961504
Content hash
8259d89d1d6d2682fb69c8ee30cec8c2d1247ce52837fadea82340360bd321ab